BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt-February 2024-www.financetom.com

BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Dec 3, 2024 5:05 AM

Dec 3 (Reuters) -

* ACCORD BIOPHARMA ANNOUNCES AGREEMENT BY INTAS

PHARMACEUTICALS,

LTD. TO ACQUIRE UDENYCA® (PEGFILGRASTIM-CBQV) BUSINESS FROM

COHERUS BIOSCIENCES, INC., UNLOCKING POTENTIAL FOR CONTINUED

U.S. GROWTH

Source text:

Previous page： Hubbell raises annual profit forecast on strong demand for power grid equipment Next page： Standex International Fiscal Q1 Adjusted Earnings, Net Sales Fall

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hubbell raises annual profit forecast on strong demand for power grid equipment

Nov 3, 2024

Oct 29 (Reuters) - Electrical equipment maker Hubbell on Thursday raised its 2024 adjusted profit forecast anticipating strong demand for its devices used in power grids. The Connecticut-based company now expects full-year adjusted profit to be between $16.35 and $16.55 per share, above its earlier expectations of between $16.20 and $16.50 per share. Hubbell has benefited from the ongoing U.S....

Standex International Fiscal Q1 Adjusted Earnings, Net Sales Fall

Nov 3, 2024

08:08 AM EDT, 10/29/2024 (MT Newswires) -- Standex International ( SXI ) reported fiscal Q1 adjusted earnings Tuesday of $1.71 per diluted share, down from $1.74 a year ago. Four analysts polled by Capital IQ expected $1.65. Net sales for the quarter ended Sept. 30 were $170.5 million, down from $184.8 million a year earlier. Analysts surveyed by Capital IQ...

Kiniksa Pharmaceuticals Q3 Loss Narrows, Revenue Rises

Nov 3, 2024

08:09 AM EDT, 10/29/2024 (MT Newswires) -- Kiniksa Pharmaceuticals International (KNSA) reported a Q3 loss Tuesday of $0.18 per diluted share, narrower than a loss of $0.20 a year earlier. Analysts surveyed by Capital IQ expected a profit of $0.10. Revenue for the quarter ended Sept. 30 was $112.2 million, compared with $67 million a year earlier. Analysts surveyed by...

Shutterstock's Q3 Adjusted Net Income, Revenue Rise; 2024 Guidance Revised; CFO Yahes Departing

Nov 3, 2024

08:05 AM EDT, 10/29/2024 (MT Newswires) -- Shutterstock ( SSTK ) reported Q3 adjusted net income Tuesday of $1.31 per diluted share, up from $1.26 a year earlier. Three analysts polled by Capital IQ expected $1.13. Revenue for the quarter ended Sept. 30 was $250.6 million, up from $233.2 million a year earlier. Four analysts surveyed by Capital IQ expected...